Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

BACKGROUND: Optimal drug treatment for patients with resistant hypertension is undefined. We aimed to test the hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone would therefore be superior to non-diuretic add-on drugs at lowering blood...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lancet
Main Authors: Williams, Bryan, MacDonald, Thomas M, Morant, Steve, Webb, David J, Sever, Peter, McInnes, Gordon, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Salsbury, Jackie, Mackenzie, Isla, Padmanabhan, Sandosh, Brown, Morris J
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2015
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4655321/
https://ncbi.nlm.nih.gov/pubmed/26414968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00257-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares